SCHEMBL2335110

SCHEMBL2335110

O=C(O)c1ccc2c(c1)ncn2-c1ccc(-n2cccn2)cc1

nearest known ligand 0.70

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 9/20 0.70
THRB P10828 1/20 0.59
HPGD P15428 4/20 0.58
LMNA P02545 2/20 0.52
ALDH1A1 P00352 1/20 0.52
KDM5A P29375 1/20 0.48
KDM2B Q8NHM5 1/20 0.48
KDM4C Q9H3R0 1/20 0.48
KDM5B Q9UGL1 1/20 0.48
HCAR3 P49019 1/20 0.46
GSK3B P49841 1/20 0.46
TSHR P16473 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28685131 0.84 FGFR1 (0.85) FGFR1THRBHPGDLMNAALDH1A1
SCHEMBL29987340 0.84 FGFR1 (0.85) FGFR1THRBHPGDLMNAALDH1A1
SCHEMBL122653 0.83 FGFR1 (1.00) FGFR1THRBHPGDLMNAALDH1A1
SCHEMBL30343716 0.83 FGFR1 (1.00) FGFR1THRBHPGDLMNAALDH1A1
SCHEMBL121454 0.82 FGFR1 (0.76) FGFR1THRBHPGDLMNAALDH1A1
Hydrochloric Acid SCHEMBL7986291 0.82 FGFR1 (0.97) FGFR1THRBHPGDLMNAALDH1A1
SCHEMBL4505231 0.80 FGFR1 (0.78) FGFR1THRBHPGDLMNAALDH1A1
SCHEMBL14065328 0.79 KMT2A (0.52) FGFR1HPGDLMNA
SCHEMBL14065338 0.79 FGFR1 (0.76) FGFR1THRBHPGDLMNAALDH1A1
SCHEMBL2339316 0.79 FGFR1 (0.76) FGFR1THRBHPGDLMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1831206-B1 N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS AND COMBINATORIAL BENZIMIDAZOLE LIBRARY OSI PHARM INC (US) 2011-08-24 EP disclosed
US-7419995-B2 N-substituted benzimidazoyl c-Kit inhibitors and combinatorial benzimidazole library OSI PHARMACEUTICALS, INC. (US) 2008-09-02 US disclosed
US-7419995-B2 N-substituted benzimidazoyl c-Kit inhibitors and combinatorial benzimidazole library OSI PHARMACEUTICALS, INC. (US) 2008-09-02 US disclosed
US-7419995-B2 N-substituted benzimidazoyl c-Kit inhibitors and combinatorial benzimidazole library OSI PHARMACEUTICALS, INC. (US) 2008-09-02 US disclosed
EP-1831206-A2 N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS AND COMBINATORIAL BENZIMIDAZOLE LIBRARY OSI Pharmaceuticals, Inc. (US) 2007-09-12 EP disclosed
WO-2006060381-A2 N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS AND COMBINATORIAL BENZIMIDAZOLE LIBRARY OSI PHARMACEUTICALS, INC. (US) 2006-06-08 WO disclosed
US-20060116402-A1 N-substituted benzimidazolyl c-Kit inhibitors and combinatorial benzimidazole library OSI PHARMACEUTICALS, INC. 2006-06-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060116402-A1 N-substituted benzimidazolyl c-Kit inhibitors and combinatorial benzimidazole library KIT, CHUK, TNNI3K FGFR1 1333/4885THRB 3985/4885HPGD 1642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.